Published in Immunol Allergy Clin North Am on November 01, 2010
Rhinovirus-Infected Epithelial Cells Produce More IL-8 and RANTES Compared With Other Respiratory Viruses. Allergy Asthma Immunol Res (2013) 0.81
Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics (1998) 49.00
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol (1969) 10.85
Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med (2005) 9.47
Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ (1995) 9.26
Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet (1999) 7.90
The major human rhinovirus receptor is ICAM-1. Cell (1989) 7.81
Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat Immunol (2000) 7.78
Oral prednisolone for preschool children with acute virus-induced wheezing. N Engl J Med (2009) 7.24
Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med (2008) 6.35
National surveillance for asthma--United States, 1980-2004. MMWR Surveill Summ (2007) 6.05
Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med (2000) 5.24
Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol (2007) 4.54
A diverse group of previously unrecognized human rhinoviruses are common causes of respiratory illnesses in infants. PLoS One (2007) 4.40
Severe respiratory syncytial virus bronchiolitis in infancy and asthma and allergy at age 13. Am J Respir Crit Care Med (2004) 4.32
Pan-viral screening of respiratory tract infections in adults with and without asthma reveals unexpected human coronavirus and human rhinovirus diversity. J Infect Dis (2007) 4.16
Association of Chlamydia pneumoniae (strain TWAR) infection with wheezing, asthmatic bronchitis, and adult-onset asthma. JAMA (1991) 3.99
Respiratory syncytial viral infection in infants with congenital heart disease. N Engl J Med (1982) 3.93
Links between innate and adaptive immunity via type I interferon. Curr Opin Immunol (2002) 3.91
Asthma and allergy patterns over 18 years after severe RSV bronchiolitis in the first year of life. Thorax (2010) 3.84
Multiplex PCR for typing and subtyping influenza and respiratory syncytial viruses. J Clin Microbiol (1998) 3.78
Primary respiratory syncytial virus infection in mice. J Med Virol (1988) 3.77
Respiratory syncytial virus infection of human airway epithelial cells is polarized, specific to ciliated cells, and without obvious cytopathology. J Virol (2002) 3.74
Inhibition of respiratory viruses by nasally administered siRNA. Nat Med (2004) 3.69
Many rhinovirus serotypes share the same cellular receptor. J Virol (1984) 3.59
Evidence for the direct involvement of the rhinovirus canyon in receptor binding. Proc Natl Acad Sci U S A (1988) 3.29
Respiratory viral infection in childhood. A survey in general practice, Roehampton 1967-1972. J Hyg (Lond) (1975) 3.19
A randomized trial of montelukast in respiratory syncytial virus postbronchiolitis. Am J Respir Crit Care Med (2002) 3.18
Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med (2008) 3.17
Frequency, severity, and duration of rhinovirus infections in asthmatic and non-asthmatic individuals: a longitudinal cohort study. Lancet (2002) 3.11
Intercellular adhesion molecule-1. J Mol Med (Berl) (1996) 2.94
Asthma and immunoglobulin E antibodies after respiratory syncytial virus bronchiolitis: a prospective cohort study with matched controls. Pediatrics (1995) 2.87
Efficacy and safety of oral pleconaril for treatment of colds due to picornaviruses in adults: results of 2 double-blind, randomized, placebo-controlled trials. Clin Infect Dis (2003) 2.81
Respiratory picornaviruses and respiratory syncytial virus as causative agents of acute expiratory wheezing in children. Emerg Infect Dis (2004) 2.68
Prevalence of viral respiratory tract infections in children with asthma. J Allergy Clin Immunol (2006) 2.67
Bovine respiratory syncytial virus nonstructural proteins NS1 and NS2 cooperatively antagonize alpha/beta interferon-induced antiviral response. J Virol (2000) 2.62
Dysregulated T helper cell differentiation in the absence of interferon regulatory factor 4. Proc Natl Acad Sci U S A (2002) 2.61
VP1 sequencing of all human rhinovirus serotypes: insights into genus phylogeny and susceptibility to antiviral capsid-binding compounds. J Virol (2004) 2.56
Lower airways inflammation during rhinovirus colds in normal and in asthmatic subjects. Am J Respir Crit Care Med (1995) 2.48
Serial viral infections in infants with recurrent respiratory illnesses. Eur Respir J (2008) 2.46
Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol (2007) 2.45
Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma. Am J Respir Crit Care Med (1998) 2.45
Mouse models of rhinovirus-induced disease and exacerbation of allergic airway inflammation. Nat Med (2008) 2.44
Role of viruses and bacteria in acute wheezy bronchitis in childhood: a study of sputum. Arch Dis Child (1979) 2.44
Role of respiratory viruses in acute upper and lower respiratory tract illness in the first year of life: a birth cohort study. Pediatr Infect Dis J (2006) 2.44
Infective factors in exacerbations of bronchitis and asthma. Br Med J (1972) 2.41
The Tucson Children's Respiratory Study. I. Design and implementation of a prospective study of acute and chronic respiratory illness in children. Am J Epidemiol (1989) 2.33
Mechanisms of receptor-mediated rhinovirus neutralization defined by two soluble forms of ICAM-1. J Virol (1991) 2.30
Relationship of upper and lower airway cytokines to outcome of experimental rhinovirus infection. Am J Respir Crit Care Med (2000) 2.29
Viral infection in adults hospitalized with community-acquired pneumonia: prevalence, pathogens, and presentation. Chest (2008) 2.26
CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat Immunol (2001) 2.21
Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol (2005) 2.18
Rhinovirus outbreak in a long term care facility for elderly persons associated with unusually high mortality. Clin Infect Dis (2005) 2.18
Viral respiratory tract infection and exacerbations of asthma in adult patients. Thorax (1988) 2.15
Respiratory syncytial virus infection results in airway hyperresponsiveness and enhanced airway sensitization to allergen. J Clin Invest (1997) 2.10
Respiratory syncytial virus nonstructural proteins NS1 and NS2 mediate inhibition of Stat2 expression and alpha/beta interferon responsiveness. J Virol (2005) 2.09
Evaluation of the safety, tolerability and pharmacokinetics of ALN-RSV01, a novel RNAi antiviral therapeutic directed against respiratory syncytial virus (RSV). Antiviral Res (2007) 2.06
Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med (2004) 2.06
New complete genome sequences of human rhinoviruses shed light on their phylogeny and genomic features. BMC Genomics (2007) 1.97
The effect of respiratory syncytial virus on subsequent recurrent wheezing in atopic and nonatopic children. J Allergy Clin Immunol (2010) 1.97
Viral infection in wheezy bronchitis and asthma in children. Arch Dis Child (1976) 1.95
Genome-wide diversity and selective pressure in the human rhinovirus. Virol J (2007) 1.94
A randomized, double-blind, placebo-controlled study of an RNAi-based therapy directed against respiratory syncytial virus. Proc Natl Acad Sci U S A (2010) 1.92
Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. Eur Respir J (2002) 1.92
Practice imperfect--treatment for wheezing in preschoolers. N Engl J Med (2009) 1.90
Multistage regulation of Th1-type immune responses by the transcription factor IRF-1. Immunity (1997) 1.89
Respiratory syncytial virus-induced chemokine production: linking viral replication to chemokine production in vitro and in vivo. J Infect Dis (2004) 1.87
Comparison of human metapneumovirus, respiratory syncytial virus and influenza A virus lower respiratory tract infections in hospitalized young children. Pediatr Infect Dis J (2006) 1.86
The crystal structure of coxsackievirus A21 and its interaction with ICAM-1. Structure (2005) 1.82
Respiratory syncytial virus up-regulates TLR4 and sensitizes airway epithelial cells to endotoxin. J Biol Chem (2003) 1.80
Rhinovirus replication causes RANTES production in primary bronchial epithelial cells. Am J Respir Cell Mol Biol (1999) 1.77
Extrapulmonary manifestations of severe respiratory syncytial virus infection--a systematic review. Crit Care (2006) 1.72
Analysis of respiratory syncytial virus F, G, and SH proteins in cell fusion. Virology (1994) 1.72
The role of viruses in acute exacerbations of asthma. J Allergy Clin Immunol (2010) 1.71
Rhinovirus infections in Tecumseh, Michigan: frequency of illness and number of serotypes. J Infect Dis (1987) 1.69
Respiratory syncytial virus infection in infants is associated with predominant Th-2-like response. Am J Respir Crit Care Med (1997) 1.67
Molecular mechanism of paramyxovirus budding. Virus Res (2004) 1.65
Eosinophils, eosinophil ribonucleases, and their role in host defense against respiratory virus pathogens. J Leukoc Biol (2001) 1.62
Inflammation and structural changes in the airways of patients with atopic and nonatopic asthma. BHR Group. Am J Respir Crit Care Med (2000) 1.58
T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A (1998) 1.58
Eosinophils contribute to innate antiviral immunity and promote clearance of respiratory syncytial virus. Blood (2007) 1.52
Toll-like receptor 3 is induced by and mediates antiviral activity against rhinovirus infection of human bronchial epithelial cells. J Virol (2005) 1.52
Detection of viral, Chlamydia pneumoniae and Mycoplasma pneumoniae infections in exacerbations of asthma in children. J Clin Virol (1999) 1.51
Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol (1998) 1.50
Recurrent wheezy bronchitis and viral respiratory infections. Arch Dis Child (1991) 1.49
Roles of interferon-regulatory factors in T-helper-cell differentiation. Nat Rev Immunol (2005) 1.49
A defective type 1 response to rhinovirus in atopic asthma. Thorax (2002) 1.48
Secreted respiratory syncytial virus G glycoprotein induces interleukin-5 (IL-5), IL-13, and eosinophilia by an IL-4-independent mechanism. J Virol (1999) 1.42
Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc (2005) 1.42
Pharmacologic advances in the treatment and prevention of respiratory syncytial virus. Clin Infect Dis (2010) 1.36
Mycoplasma pneumoniae respiratory disease symposium: summation and significance. Yale J Biol Med (1984) 1.34
Evidence for the role of the P2 protein of human rhinovirus in its host range change. J Virol (1989) 1.34
RSV604, a novel inhibitor of respiratory syncytial virus replication. Antimicrob Agents Chemother (2007) 1.34
IFN-gamma represses IL-4 expression via IRF-1 and IRF-2. Immunity (2002) 1.32
Respiratory syncytial virus induces selective production of the chemokine RANTES by upper airway epithelial cells. J Infect Dis (1997) 1.31
Antileukotriene drugs: clinical application, effectiveness and safety. Curr Med Chem (2007) 1.29
Similar colds in subjects with allergic asthma and nonatopic subjects after inoculation with rhinovirus-16. J Allergy Clin Immunol (2009) 1.28
Efficacy of tremacamra, a soluble intercellular adhesion molecule 1, for experimental rhinovirus infection: a randomized clinical trial. JAMA (1999) 1.28
Inhibition of respiratory syncytial virus infection with intranasal siRNA nanoparticles targeting the viral NS1 gene. Nat Med (2004) 2.06
Adherence to antiretroviral therapy in India: a systematic review and meta-analysis. Indian J Community Med (2013) 1.16
Natriuretic peptide receptor a as a novel anticancer target. Cancer Res (2008) 1.14
Multifunctional magnetic nanoparticles for targeted delivery. Nanomedicine (2009) 1.03
Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans. J Nanosci Nanotechnol (2006) 0.98
A 3D fibrous scaffold inducing tumoroids: a platform for anticancer drug development. PLoS One (2013) 0.97
Respiratory syncytial virus NS1 protein colocalizes with mitochondrial antiviral signaling protein MAVS following infection. PLoS One (2012) 0.94
Natriuretic peptide receptor a as a novel target for prostate cancer. Mol Cancer (2011) 0.91
Designer monoclonal antibodies as drugs: the state of the art. Expert Rev Clin Immunol (2008) 0.91
Nanoparticle-mediated gene delivery: state of the art. Expert Opin Biol Ther (2004) 0.90
Attenuation of dengue virus infection by adeno-associated virus-mediated siRNA delivery. Genet Vaccines Ther (2004) 0.89
Sensitive estimation of total cholesterol in blood using Au nanowires based micro-fluidic platform. Biosens Bioelectron (2007) 0.88
Microbes and asthma: the missing cellular and molecular links. Curr Opin Pulm Med (2012) 0.87
Aging enhances vascular dysfunction induced by the Alzheimer's peptide beta-amyloid. Neurol Res (2004) 0.84
Modulation of lung inflammation by vessel dilator in a mouse model of allergic asthma. Respir Res (2009) 0.84
CCL20 Is Associated with Neurodegeneration Following Experimental Traumatic Brain Injury and Promotes Cellular Toxicity In Vitro. Transl Stroke Res (2012) 0.80
Regulating the Regulators: microRNA and Asthma. World Allergy Organ J (2011) 0.80
Immunotherapy for allergies and asthma: present and future. Curr Opin Pharmacol (2010) 0.79
Nanotechnology Applications to HIV Vaccines and Microbicides. J Glob Infect Dis (2012) 0.78
Initial observations of cell-mediated drug delivery to the deep lung. Cell Transplant (2010) 0.77
Transverse susceptibility as a biosensor for detection of Au-Fe₃O₄ nanoparticle-embedded human embryonic kidney cells. Sensors (Basel) (2013) 0.75
Chitosan-Modified Graphene Electrodes for DNA Mutation Analysis. J Electroanal Chem (Lausanne) (2012) 0.75
Infectious Diseases and Asthma. Preface. Immunol Allergy Clin North Am (2010) 0.75